May 29, 2016

Bioengineered human acellular vessels for dialysis access in patients with end-stage renal disease: two phase 2 single-arm trials

.   .   

This phase 2 trial looked at bioengineered human acellular vessel as an option for dialysis access in 60 patients that were not candidates for arteriovenous fistulas.  The results show that onne vessel became infected during 82 patient-years of follow-up. There were no vessels with dilatation and there was rarely any post-cannulation bleeding. At 12 months, 28% (17–40) had primary patency, 38% (26–51) had primary assisted patency, and 89% (74–93) had secondary patency.  These result certainly warrant further study with a randomized controlled trial.

 

Related Articles:

Hemodialysis, Vascular Access